» Articles » PMID: 38757071

Human Plasma Derived Exosomes: Impact of Active and Passive Drug Loading Approaches on Drug Delivery

Abstract

The aim of the current study was to explore the potential of human plasma-derived exosomes as versatile carriers for drug delivery by employing various active and passive loading methods. Exosomes were isolated from human plasma using differential centrifugation and ultrafiltration method. Drug loading was achieved by employing sonication and freeze thaw methods, facilitating effective drug encapsulation within exosomes for delivery. Each approach was examined for its effectiveness, loading efficiency and ability to preserve membrane stability. Methotrexate (MTX), a weak acid model drug was loaded at a concentration of 2.2 µM to exosomes underwent characterization using various techniques such as particle size analysis, transmission electron microscopy and drug loading capacity. Human plasma derived exosomes showed a mean size of 162.15 ± 28.21 nm and zeta potential of -30.6 ± 0.71 mV. These exosomes were successfully loaded with MTX demonstrated a better drug encapsulation of 64.538 ± 1.54 % by freeze thaw method in comparison 55.515 ± 1.907 % by sonication. drug release displayed 60 % loaded drug released within 72 h by freeze thaw method that was significantly different from that by sonication method i.e., 99 % within 72 h (p value 0.0045). Moreover, cell viability of exosomes loaded by freeze thaw method was significantly higher than that by sonication method (p value 0.0091) suggested that there was membrane disruption by sonication method. In conclusion, this study offers valuable insights into the potential of human plasma-derived exosomes loaded by freeze thaw method suggest as a promising carrier for improved drug loading and maintenance of exosomal membrane integrity.

Citing Articles

Human Plasma-Derived Exosomes: A Promising Carrier System for the Delivery of Hydroxyurea to Combat Breast Cancer.

Khalid W, Aslam A, Ahmed N, Sarfraz M, Khan J, Mohsin S AAPS PharmSciTech. 2025; 26(1):42.

PMID: 39843767 DOI: 10.1208/s12249-024-03028-w.

References
1.
Haney M, Klyachko N, Zhao Y, Gupta R, Plotnikova E, He Z . Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015; 207:18-30. PMC: 4430381. DOI: 10.1016/j.jconrel.2015.03.033. View

2.
Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari M, Nomani A, Azizi E . Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine. 2009; 6(3):478-85. DOI: 10.1016/j.nano.2009.10.003. View

3.
Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X . Current Strategies for Exosome Cargo Loading and Targeting Delivery. Cells. 2023; 12(10). PMC: 10216928. DOI: 10.3390/cells12101416. View

4.
He X, Zhang C, Amirsaadat S, Turki Jalil A, Kadhim M, Abasi M . Curcumin-Loaded Mesenchymal Stem Cell-Derived Exosomes Efficiently Attenuate Proliferation and Inflammatory Response in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Appl Biochem Biotechnol. 2022; 195(1):51-67. DOI: 10.1007/s12010-022-04090-5. View

5.
Kalluri R, LeBleu V . Discovery of Double-Stranded Genomic DNA in Circulating Exosomes. Cold Spring Harb Symp Quant Biol. 2017; 81:275-280. DOI: 10.1101/sqb.2016.81.030932. View